IRWD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IRWD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Ironwood Pharmaceuticals's change in inventory for the quarter that ended in Sep. 2024 was $0.0 Mil. It means Ironwood Pharmaceuticals's inventory stayed the same from Jun. 2024 to Sep. 2024 .
Ironwood Pharmaceuticals's change in inventory for the fiscal year that ended in Dec. 2023 was $0.0 Mil. It means Ironwood Pharmaceuticals's inventory stayed the same from Dec. 2022 to Dec. 2023 .
Ironwood Pharmaceuticals's Total Inventories for the quarter that ended in Sep. 2024 was $0.0 Mil.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Ironwood Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Sep. 2024 was 0.00.
The historical data trend for Ironwood Pharmaceuticals's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ironwood Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Change In Inventory | Get a 7-Day Free Trial | - | 0.65 | - | - | - |
Ironwood Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Change In Inventory | Get a 7-Day Free Trial | - | - | - | - | - |
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ironwood Pharmaceuticals (NAS:IRWD) Change In Inventory Explanation
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Ironwood Pharmaceuticals's Days Inventory for the quarter that ended in is calculated as:
Days Inventory | = | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period |
= | 0 | / | 0 | * | 365 / 4 | |
= | N/A |
2. Inventory Turnover measures how fast the company turns over its inventory within a year.
Ironwood Pharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2024 is calculated as
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 0 | / | 0 | |
= | N/A |
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Ironwood Pharmaceuticals's Inventory to Revenue for the quarter that ended in Sep. 2024 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 0 | / | 91.592 | |
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Ironwood Pharmaceuticals's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Andrew Davis | officer: SVP, Chief Business Officer | 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110 |
Sravan Kumar Emany | officer: SVP, Chief Financial Officer | 100 SUMMER ST, SUITE 2300, BOSTON MA 02109 |
Ronald Silver | officer: Principal Accounting Officer | 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110 |
Minardo John | officer: Chief Legal Officer | 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110 |
Julie Mchugh | director | C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110 |
Catherine Moukheibir | director | C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110 |
Michael Shetzline | officer: CMO,SVP,Head-Res&Drug | 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110 |
Thomas A Mccourt | officer: Chief Commercial Officer | C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110 |
Jon R Duane | director | C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110 |
Marla L Kessler | director | C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110 |
Jason Rickard | officer: SVP, Chief Operating Officer | 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110 |
Mark G Currie | officer: Chief Scientific Officer | C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142 |
Sarissa Capital Management Lp | 10 percent owner | 660 STEAMBOAT ROAD, GREENWICH CT 06830 |
Alexander J Denner | director | C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
Gina Consylman | officer: Chief Accounting Officer | C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110 |
From GuruFocus
By GuruFocus Research • 08-08-2024
By GuruFocus News • 10-09-2024
By Business Wire • 08-08-2024
By Business Wire • 07-25-2024
By Business Wire • 05-30-2024
By GuruFocus News • 11-08-2024
By Business Wire • 04-25-2024
By GuruFocus Research • 06-10-2024
By GuruFocus News • 11-15-2024
By GuruFocus Research • 05-10-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.